Abstracts Archive - Page 178 of 2607 - ACR Meeting Abstracts

Abstract Number: 1040 • ACR Convergence 2025
Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
Cristina Hurley¹, Megha Kotha², Jisna Paul³ and Jeff Barbee⁴, ¹Carilion Clinic, Roanoke, VA, ²Ohio State University, Columbus, OH, ³Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, ⁴Ohio State University Wexner Medical Center, Columbus
Background/Purpose: This study assesses the impact of a clinical pharmacist-directed intervention on medication adherence and clinical outcomes in patients with rheumatoid arthritis, psoriatic arthritis, and…
Abstract Number: 1301 • ACR Convergence 2025
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
Sirikarn Tangcheewinsirikul¹, Zhaoyu Ding², Nicholas Chan³, Daniela Dominguez³, Andrea Knight⁴, Deborah Levy¹, Lawrence Ng⁵, Earl Silverman¹, Ruud Verstegen¹ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and…
Abstract Number: 1287 • ACR Convergence 2025
A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Ivan Foeldvari¹, Kathryn Torok², Ozgur Kasapcopur³, Amra Adrovic⁴, Flavio Sztajnbok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Raju Khubchandani⁹, Sindhu Johnson¹⁰, Gülcan Özomay Baykal¹¹, Brian Feldman¹², Dieneke Schonenberg-Meinema¹³, Sujata Sawhney¹⁴, Vanessa Smith¹⁵, Eslam Al-Abadi¹⁶, Simone Appenzeller¹⁷, Stefanie Hajek¹⁸, Maria Katsicas¹⁹, Mikhail Kostik²⁰, Suzanne Li²¹, Hana Malcova²², Anjali Patwardhan²³, Walter Alberto Sifuentes-Giraldo²⁴, Natalia Vasquez-Canizares²⁵, Tadej Avcin²⁶, Patricia Costa Reis²⁷, Siri Opsahl Hetlevik²⁸, Mahesh Janarthanan²⁹, Edoardo Marrani³⁰, Clare Pain³¹, Maria Jose Santos³², Valda Stanevica³³, Sima Abu Alsaoud³⁴, Ekaterina Alexeeva³⁵, Cristina Battagliotti³⁶, Lillemor Berntson³⁷, blanca e r bica³⁸, Jürgen Brunner³⁹, Despina Eleftheriou⁴⁰, Liora Harel⁴¹, Tilmann Kallinich⁴², Dragana Lazarevic⁴³, Kirsten Minden⁴⁴, Dana Nemcova⁴⁵, Susan Nielsen⁴⁶, Farzana Nuruzzaman⁴⁷, Mihaela Sparchez⁴⁸, Yosef Uziel⁴⁹ and Nicola Helmus⁵⁰, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Turkey, Turkey, ⁵UFRJ/UERJ, SAO PAULO, Brazil, ⁶UNIFESP, São Paulo, São Paulo, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil, ⁸Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Jaslok Hospital and Research Center, Mumbai, India, ¹⁰Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Umraniye Training and Research Hospital, Istanbul, Turkey, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁴Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁷Unicamp, Campinas, São Paulo, Brazil, ¹⁸Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ¹⁹Hospital Garrahan, Buenos Aires, Argentina, ²⁰Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²¹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ²²Motol University Hospital, Prague, Czech Republic, ²³University of Missouri-Columbia, Columbia, MO, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Children’s Hospital at Montefiore, Bronx, NY, ²⁶University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²⁷Hospital de Santa Maria, Lisbon, Portugal, ²⁸Oslo University Hospital, Oslo, Norway, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁰Meyer Children Hospital IRCCS, Firenze, Italy, ³¹Alder Hey NHS Trust, Liverpool, United Kingdom, ³²Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³³Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ³⁴Caritas baby Hospital, Jerusalem, Palestine, ³⁵National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ³⁶Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁷Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁸UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ³⁹Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴⁰Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴¹Schneider Children's Medical center, Nettnja, Israel, ⁴²Charite University Medicine Berlin, Berlin, Germany, ⁴³Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁴German Rheumatism Research Center, Berlin, Germany, ⁴⁵Charles University, Prague, Czech Republic, ⁴⁶Rigshospitalet, Copenhagen, Denmark, ⁴⁷Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁸Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, ⁴⁹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁵⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis(jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult systemic sclerosis is interstitial lung…
Abstract Number: 1062 • ACR Convergence 2025
Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Alejandro Balsa⁴, Chamaida Plasencia-Rodríguez⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Sex-related differences in axial spondyloarthritis (axSpA) have been described regarding clinical features, disease burden, and particularly patient-reported outcomes. These differences influence patient management, including…
Abstract Number: 1296 • ACR Convergence 2025
Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Meredith Rae¹, Dawn Gist², Kaylani Patel³, Krupa Mysore³, Andrea Ramirez², Marietta De Guzman² and Eyal Muscal², ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston
Background/Purpose: Distinguishing lupus hepatitis (LH) from autoimmune hepatitis (AIH) in SLE is clinically challenging but critical for guiding treatment duration. The mechanisms differ; AIH results…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…
Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Isabella Hartel¹, David Gazeley², Jay Patel¹, Betty Chewning³, Shelby Gomez⁴, Jessica Michaud⁵, Laura Dickmann⁶, Jon keevil⁷, Patricia Tellez-giron¹, Christie Bartels⁸ and Shivani Garg⁹, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷N/A, Madison, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1209 • ACR Convergence 2025
Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Jia Shi¹, Alexander Carpenter², Christopher Wong², Qian Wang³, Christian Lood⁴ and Susan Shenoi⁵, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, Seattle Children's Hospital and Research Center, Seattle, ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁴University of Washington, Division of Rheumatology, Seattle, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: To evaluate the measurement properties of functional performance measures (FPMs)—broad jump (BJ) and 10-meter run (10MR)—for assessing muscle function and disease activity in children…
Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Bandana Jassal¹, Aishwarya Dhall¹, Mohammed Faruq², Danveer Bhadu¹, Uma Kumar¹ and Mehar Chand Sharma¹, ¹All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India, ²Institute of Genomics and Integrative Biology, New Delhi, Delhi, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…
Abstract Number: 1254 • ACR Convergence 2025
Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
Lesley Arnold¹, Zhao Yang², Parul Houston², Todd Grinnell² and Daniel Clauw³, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²Axsome Therapeutics, Inc, New York, NY, ³Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…
Abstract Number: 1297 • ACR Convergence 2025
Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.
MUNIRA ALMARRI, Deena Alwakeel, Abdulaziz Alrowais and Abdulrahman Asiri, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Background/Purpose: Scleroderma is autoimmune disease that may result in changes to the skin, blood vessels, muscles, and internal organs. It can be either Localized Scleroderma…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].